Metagenomi Inc expected to post a loss of 62 cents a share - Earnings Preview

Metagenomi Therapeutics

05/08/2025 22:02

Metagenomi Inc MGX.OQ MGX.O is expected to  show a fall in quarterly revenue when it reports  results on August 7 (estimated) for the period ending June 30 2025

The Emeryville California-based  company is expected to report a 61.4% decrease in revenue to $7.72 million from $20.01 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Metagenomi Inc is for a loss of 62 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Metagenomi Inc is $10.00, about 77% above its last closing price of $2.30

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.50
-0.58
-0.68
Missed
-17.6
Dec. 31 2025
-0.66
-0.75
-0.63
Beat
16
Sep. 30 2024
-0.77
-0.78
-0.51
Beat
34.3​
Jun. 30 2024
-0.62
-0.65
-0.29
Beat
55.6
​​Mar. 31 2024
-0.72
-0.78
-1.19
Missed
-53.2
Dec. 31 2023
-2.04
-2.04
-0.51
Beat
74.8​

This summary was machine generated August 5 at 21:02 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)